Adjuvant Therapy for Renal Cell Carcinoma

被引：8

作者：

Haas, Naomi B. ^{[1
]}

Uzzo, Robert ^{[1
]}

机构：

[1] Abramson Canc Ctr, Philadelphia, PA 19104 USA

来源：

CURRENT ONCOLOGY REPORTS | 2008年 / 10卷 / 03期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1007/s11912-008-0037-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Currently, the management of localized renal cell carcinoma (RCC) is surgical. Unfortunately, many cases of high-risk RCC recur following resection and develop metastatic disease, an event that usually results in death. Because previous attempts to improve survival with adjuvant therapy have been unsuccessful, the US Food and Drug Administration's approval of three new agents for metastatic RCC has generated renewed interest in evaluating agents in the adjuvant setting for high-risk RCC. This article discusses the rationale for the use of these and other novel agents and reviews currently ongoing adjuvant trials as well as considerations for the development of new trials for adjuvant therapies.

引用

页码：245 / 252

页数：8

共 68 条

[1]

ALBERS MW, 1993, J BIOL CHEM, V268, P22825

[2]

Prognostic impact of histologic Subtyping of adult renal epithelial neoplasms - An experience of 405 cases [J].

Amin, MB ;

Tamboli, P ;

Javidan, J ;

Stricker, H ;

Venturina, MD ;

Deshpande, A ;

Menon, M .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (03) :281-291

[3]

[Anonymous], 2004, PATHOLOGY GENETICS T

[4]

[Anonymous], 2004, SUN INV BROCH

[5]

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[6]

Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy:: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) [J].

Atzpodien, J ;

Schmitt, E ;

Gertenbach, U ;

Fornara, P ;

Heynemann, H ;

Maskow, A ;

Ecke, M ;

Wöltjen, HH ;

Jentsch, H ;

Wieland, W ;

Wandert, T ;

Reitz, M .

BRITISH JOURNAL OF CANCER, 2005, 92 (05) :843-846

[7]

Avigan DE, 2004, J CLIN ONCOL, V22, p169S

[8]

Bleumer Ivar, 2006, Can J Urol, V13 Suppl 2, P57

[9]

Radical nephrectomy with and without lymph node dissection:: Preliminary results of the EORTC randomized phase III protocol 30881 [J].

Blom, JHM ;

van Poppel, H ;

Marechal, JM ;

Jacqmin, D ;

Sylvester, R ;

Schröder, FH ;

de Prijck, L .

EUROPEAN UROLOGY, 1999, 36 (06) :570-575

[10]

A MAMMALIAN PROTEIN TARGETED BY G1-ARRESTING RAPAMYCIN-RECEPTOR COMPLEX [J].

BROWN, EJ ;

ALBERS, MW ;

SHIN, TB ;

ICHIKAWA, K ;

KEITH, CT ;

LANE, WS ;

SCHREIBER, SL .

NATURE, 1994, 369 (6483) :756-758

← 1 2 3 4 5 6 7 →